icon-folder.gif   Conference Reports for NATAP  
 
  18th International Workshop on
Clinical Pharmacology of Antiviral Therapy
June 14-17, 2017
Chicago, Ill.C
Back grey_arrow_rt.gif
 
 
 
Evaluation of Drug-Drug Interaction Potential Between Sofosbuvir/Velpatasvir and Atorvastatin
 
 
  Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy, June 14-16, 2017, Chicago, IL
 
Rebecca Begley, Erik Mogalian, Brian McNabb, Gong Shen, Sherry Lee, John Ling, Anita Mathias
Gilead Sciences, Inc., Foster City, California, USA

EASL1

EASL2

EASL3

EASL4

EASL5

EASL6

References
 
1. Jacobson IM, et al. N Engl J Med 2013;368:1867-77; 2. Lawitz E, et al. N Engl J Med 2013;368:1878-87; 3. Lawitz E, et al. J Viral Hepat 2015;22:1011-9; 4. Curry M, et al. N Engl J Med 2015;373:2618-28; 5. Feld J, et al. N Engl J Med 2015;373:2599-607; 6. Foster G, et al. N Engl J Med 2015;373:2608-17; 7. Lennernäs H. Clin Pharmacokinet 2003;42:1141-60; 8. Lipitor [package insert]. New York, NY: Pfizer Inc, 3/2015; 9. Juxtapid [package insert]. Cambridge, MA: Aegerion Pharmaceuticals, Inc., 5/2016; 10. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc., 2/2017; 11. Mogalian E, et al. CROI 2016, abstr 100.